Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial
- 159 Downloads
ERA-223, a phase III clinical trial, was conducted globally to investigate the usefulness of radium-223 (Ra-223) administered concurrently with abiraterone acetate and prednisolone (AAP) . However, in this trial, the Ra-223 + AAP group did not exhibit increased survival and had a clearly higher incidence of bone fracture than the placebo + AAP group. In this paper, we would like to discuss the reasons why this study did not produce the anticipated outcomes, and how we should use Ra-223 in consideration of both efficacy and bone health.
Compliance with ethical standards
Conflict of interest
No author has any conflict of interest.
- 1.Smith M, Parker C, Saad F et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408–419CrossRefGoogle Scholar
- 4.Logothetis CJ, Basch E, Molina A et al (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13:1210–1217CrossRefGoogle Scholar